Research in diffuse large B-cell lymphoma identified NLRP3 inflammasome activation as a key driver of immune resistance, demonstrating its role in elevating PD-L1 levels and diminishing cytotoxic T-cell proportions - revealing a promising therapeutic target.An animal studies have demonstrated that dapansutrile, by blocking NLRP3, downregulated PD-L1 expression in vivo, diminished PD-1/TIM-3-expressing exhausted T cells, and consequently improved anti-tumor immunity while suppressing tumor growth (Lu et al., 2021). This evidence concerns the gene CD274 and neoplasm.